CI

At a glance

ClinicalIndex Comparison Record
Phase 2Completed· 30 enrolled
Drug / intervention
Donepezil +1 moredrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT01250977
NCT01250977Phase 2Completed
CompareCT.gov

The Effect of Acetylcholinesterase Inhibitors on Smoking Behavior

Abramson Cancer Center at Penn Medicine·interventional·Posted Dec 1, 2010·Updated Jul 11, 2019

In Brief

A Phase 2 clinical trial evaluating Donepezil and Placebo for Smoking. Completed, enrolled 30 participants across 1 site.

Detailed Summary

The objective of this proof-of-concept pilot study is to evaluate Donepezil HCL (Aricept) for side effects and effects on smoking behavior and performance on neurocognitive tasks in a population of dependent smokers.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsSmoking
CountriesUnited States
Collaborators--

Timeline

Phase 2CompletedFinished
2011201220132014201520162017201820192020202120222023202420252026
First PostedDec 1, 2010
Enrollment StartJan 11, 2011
Primary CompletionDec 6, 2011
TodayJul 2, 2026
Enrollment to primary: 11 monthsPosted 15.6 years ago

Interventions

Donepezildrug

Placebodrug